Navigation Links
Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line
Date:5/25/2010

Shaanxi province.

Biostar is forecasting $2.0 million in initial Zushima sales and a $6.0 million contribution to revenues during 2011, with gross margins of 55.0%.

"We are pleased with the results of these clinical trials and are looking forward to our next stages of approval for Zushima," began Chairman and CEO Rongua Wang of Biostar Pharmaceuticals, Inc. "Our development of Zushima represents two important strategic goals for Biostar. First, Zushima highlights our commitment to develop new products to expand our product portfolio. Second, Zushima paves the way for entrance into the Chinese military market, which represents a large, new addressable market. We anticipate receiving our final approvals by September of 2010 and look forward to a successful launch of Zushima," Wang concluded.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for two patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
2. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
3. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
4. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
8. Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the global pharmaceutical, ... an Investigational New Drug (IND) application for WuXi ... has been accepted for review by the China ... In September 2012, MedImmune, the global biologics research ...
(Date:3/26/2015)... 26, 2015 PRC Clinical, a Silicon-Valley ... several management and executive appointments effective immediately. , Mike ... (CFO) and member of the Board of Directors. Daniel ... and Sue Dowden will assume the position of Senior ... Chief Operations Officer (COO), has been appointed to the ...
(Date:3/26/2015)... CINCINNATI , March 26, 2015 ... NASDAQ: SHPG ) and Cincinnati Children,s Hospital ... collaboration for rare diseases. The goal of the collaboration ... treat rare diseases with high unmet medical need ... Children,s research expertise. As a nationally ranked hospital, ...
(Date:3/26/2015)... "In America," the popular news television program that airs in ... legendary film actor James Earl Jones, has announced that it ... , Botany is commonly described as the scientific study ... bit more complicated than that. Scientists and other professionals study ... the smallest bacteria known to man to the largest trees ...
Breaking Biology Technology:Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... 18 Danube Pharmaceuticals, Inc., a,privately held biopharmaceutical ... innovative drugs for ophthalmology, is pleased,to announce the ... its Chief,Executive Officer., "I am honored and ... in its history as it advances its lead ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... will present at the,Jefferies & Co. 2nd Annual Healthcare ... Wednesday, June 25, 2008., An audio webcast of ... the webcast at: http://www.alexionpharm.com . An archived version ...
... June 18 HemoCue(R) AB, a,global point-of-care diagnostic ... Incorporated (NYSE: DGX ), today announced,that its ... point-of-care,test for screening for, diagnosing and monitoring microalbuminuria ... Food and Drug Administration (FDA). With,the FDA CLIA ...
Cached Biology Technology:Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 2Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/19/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... this week on Washington DC,s Fox ... segment "The Next Great Thing", host Laura Evans ... and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... which has not been seen for nearly a century, has ... be in critical danger of extinction given that the only ... (Spain). A study reveals its characteristics and the reasons ... remains critically endangered. Researchers wants to restore this floral plant ...
... Mo. Plants do not have eyes or legs, yet ... from light. This ability, called phototropism, is controlled by a ... cells. In a paper published in The Plant Cell, ... the elusive role a critical protein plays in this molecular ...
... -- University of New Hampshire scientists have received National ... experiments can be applied to understand the behavior of ... investigate large-scale biological responses to climate and land-use change. ... natural resources and the environment (NREN) and assistant professor ...
Cached Biology News:The Murcian flower has been 'revived' after 100 years 2Protein plays role in helping plants see light 2UNH researchers receive NSF grant to 'scale up' stream ecology 2UNH researchers receive NSF grant to 'scale up' stream ecology 3
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, a ... are arrayed in quadruplicate for high-quality ... specific chip layout guarantee high validity ...
... UNIchip AV-400 contains 400 unique human ... glass slide. The proteins, all extracellular ... classification, are arrayed in quadruplicate for ... a specific chip layout guarantee high ...
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... Reticulocyte Lysate Systems(a,b,c,d) offer researchers an ... a single-tube, coupled transcription/translation system. The ... process and reduce the time required ... Standard rabbit reticulocyte lysate translations (1) ...
Biology Products: